A thrombocytopoiesis-stimulating factor (TSF or thrombopoietin) derived from human embryonic kidney (HEK) cells is known t o increase platelet production and t o increase the number of morphologically unrecognizable early megakaryocytes, ie, small acetylcholinesterase-positive (SAChE+) cells in mice. Other recent studies have concluded that interleukin-6 (IL-6) also stimulates murine megakaryocytopoiesis both in vitro and in vivo. Some workers have suggested that IL-6 is thrombopoietin. Therefore, the purpose of this study was t o compare the effects of TSF and IL-6 on percent 35S incorporation into platelets, platelet sizes, and the percentages of SAChE+ cells in C3H mice, and t o determine if they produce the same or different responses. The results showed that two or four injections of a partially purified TSF (total dose of 2 or 4 units (U) over a 1-or 2-day period) increased percent "S incorporation into platelets (P < .005) and platelet sizes (P < .005) of both normal and rebound-thrombocytotic mice when compared with values from other mice treated with human serum albumin, the carrier protein for THROMBOCYTOPOIESIS-stimulating factor (TSF A or thrombopoietin) derived from human embryonic kidney (HEK) cells is a potent stimulator of thrombocytopoiesis and megakaryocytopoiesis.' Previous work showed that, in vivo, TSF stimulates increases in megakaryocyte size and number, the number of precursor megakaryocytes (ie, small acetylcholinesterase-positive [SAChE+] cells), and maturation and endomitotic indices of megakaryocytes.' More recently, it was shown that TSF increased megakaryocyte DNA content.' In addition, thrombopoietin increases platelet numbers, platelet sizes, and percent "S incorporation into platelets of mice.'.' One group of workers concluded that interleukin-6 (IL-6) functions as thrombopoietin.' In recent work it was shown that high doses (4 to 16 p.g to mice or 70 to 1120 p.@g to monkeys) of IL-6 increases platelet increases percent '%e-selenomethionine (75SeM) incorporation into platelets in a doseresponse relationship: increases megakaryocyte size? and increases the number of megakaryocyte and granulocytemacrophage colony-forming cells in bone marrow (BM) and ~p l e e n .~ White blood cell (WBC) counts were also increased after 16 p.g/mouse4 or after 70 p.@g in monkeys' by IL-6 treatment. However, the numbers of marrow megakaryocytes were not increased in mice treated with 20 to 100 p.g of IL-63 and hematocrits were reported to be normaL4 A preliminary study by Hill et al' reported that platelet sizes were not altered significantly by IL-6 administration. Moreover, several additional studies8-" concluded that IL-6 causes an increase in megakaryocytopoiesis in vitro. For example, megakaryocyte sizes, acetylcholinesterase content, and DNA content were increased in vitro in the presence of IL-6.8 Bruno and Hoffman' showed that IL-6 will increase the number of megakaryocytic colonies in the absence of IL-3, whereas these and other investigators'." concluded that pretreatment of BM cells with IL-3 before adding IL-6 will either improve' or is required"-" for increasing the number of megakaryocytic colonies.
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In all of these studies, it was concluded that IL-6 both TSF and IL-6. In eight separate experiments, it was shown that IL-6 (40,000 U, 4 pg), when given t o reboundthrombocytotic mice in four injections over a 2-day period, produced a small but significant (P < .005) increase in percent "S incorporation into platelets. Additional studies showed that negative results were obtained when similar high doses of IL-6 were administered in two doses over a 1-day period. TSF, but not IL-6, stimulated an increase in platelet sizes of normal mice (P < stimulated megakaryocytopoiesis and platelet production. However, measurement of platelet sizes after IL-6 treatment has only been reported in a preliminary study and the effects of IL-6 on SAChE+ cells have not been reported. Therefore, the purpose of the present study was to compare the effects of TSF and IL-6 on percent 3sS incorporation into platelets, platelet sizes, and the percent SAChE+ cells in the BM of C3H mice. Although both cytokines stimulated percent 35S incorporation into platelets, IL-6 did not stimulate an increase in platelet sizes of normal mice nor elevate the proportion of SAChE+ cells, indicating significant biologic differences in the two factors.
MATERIALS AND METHODS
A total of 336 C3HWENHSD (C3H; Harlan Sprague-Dawley, Indianapolis, IN) male mice weighing about 24 g each was used in these studies. Animals were injected with test materials using one of two different treatment schedules. The first schedule was as follows: mice were given one subcutaneous (SC) injection of test substance in the morning and another injection in the afternoon of the first day; these mice were killed 3 days after the first injection. The second schedule utilized a total of four injections: one injection was given in the morning and another in the afternoon of the first and second days. As before, mice were killed 3 days after the first injection. Both normal and rebound-thrombocytotic mice were used in these studies and all mice were given the same total dose of test materials. Mice were made thrombocytotic by a single intraperitoneal (IP) injection of rabbit antimouse platelet serum (RAMPS) 5 days before injection of test substances, ie, human serum albumin (HSA), TSF, or IL-6.
The TSF used in this study was Step I1 material, a partially purified preparation from HEK cell culture media.14 A total dose of 2 or 4 units (U) of TSF was given per mouse. A unit of TSF is defined as the amount of material in milligrams of protein that is required to increase the percent "S incorporation into platelets of immunothrombocythemic mice by SO% above base1ine.l4 The specific activity of the TSF used in this study was approximately 3.5 U/mg protein. The TSF preparation contained a small amount of IL-6, ie, -875 U of IL-6/U of TSF as determined by the B9 cell proliferation assay." Because large amounts of HSA (approximately 1.8 mg for each TSF U) were added to stabilize the partially purified TSF, other mice were treated with 7.5 mg of HSA as a control. Previous studies* showed that saline and HSA gave similar responses in mice, ie, platelet sizes, percent "S incorporation into platelets, and average polyploid megakaryocyte DNA content were almost identical at 2 and 3 days after the beginning of the treatment. Therefore, in the present studies, HSA was used as the control substance.
Recombinant human IL-6 (rhIL-6) was obtained from Boehringer Mannheim (Indianapolis, IN). This preparation of rhIL-6 was produced utilizing Eschen'chra coli and purified by standard chromatographic techniques. The material was greater than 98% pure as determined by sodium dodecyl sulfatepolyacrylamide gel electrophoresis (SDS-PAGE), and endotoxin (LAL) was less than 10 EU/mg. Specific activity was greater than 1 X 10' Uimg as determined by the B9 cell proliferation assay." The material was diluted into HSA (7.5 mghouse) before injection.
Percent "S incorporation into platelets and platelet sizes were measured using previously described techniques." l7 Thirty microcuries of Na,)SSO, were injected intravenously (IV) 24 hours before killing. Blood for determination of percent "S incorporation into platelets and platelet sizes was taken by cardiac puncture after injection of a heparin-sodium pentobarbital solution.'6 Approximately 0.5 mL of blood was collected into syringes containing 1 mL of 3.8% sodium citrate solution and expressed into plastic tubes. Platelet-rich plasma (PRP) was obtained by centrifugation at 16% for 4.5 minutes at 22°C. The tube containing the PRP was capped to minimize pH changes, which can alter platelet sizes. The platelets were washed and the percent "S incorporation measured as previously described. 16 Platelet size measurements were made using a Particle Data Instrument (Particle Data Inc, Elmhurst, IL) with a logarithmic scale as previously described.17 Platelet counts and hematocrits were performed on blood obtained by retroorbital puncture using standard techniques.
After bleeding, the mice were killed and marrow was taken from one of the femurs and dispersed into a single cell suspension by mixing with a plasma expander (Polyvinyl-pyrrolidone, 3.5% in saline with 1% EDTA added). Marrow smears were made and stained for the presence of acetylcholinesterase (AChE) activity using the method of Karnovsky and Roots.I8 For staining, marrow smears were rinsed in 0.1 mol/L sodium phosphate, pH 6.0, for 1 minute and then incubated in the acetylthiocholine substrate mixture at room temperature for 3 hours.'' After staining, the smears were postfixed in absolute methanol for 10 minutes and SO% methanol for 30 seconds. All AChE+ cells on each slide were counted. The SAChE+ cells stain positively for AChE, are usually round, stain evenly without granulation, and are less than 13 Fm in diameter." For each mouse, approximately 500 AChE+ cells were examined; the number of SAChE+ cells and the total number of cells that stain positively for AChE were recorded and the percentage of SAChE+ cells was calculated.
To eliminate the possibility that the small amount of IL-6 present in the TSF preparation was responsible for the stimulation of platelet sizes and percent "S incorporation into platelets found after TSF injection, an additional experiment using a more highly purified preparation of TSF (Step Ill TSF)I4 was used. This preparation of TSF (specific activity of 15.8 U/mg protein) was found to be free of IL-6 by both Western blotting techniques and by the B9 cell proliferation assay." The more highly purified TSF was injected into immunothrombocythemic assay mice in four doses over a 2-day period and the percent "S incorporation into platelets was determined as previously described. 16 Student's t-test was used for evaluation of the data. Figure 1 shows the results of dose-response studies of TSF and IL-6 on "S incorporation into platelets of reboundthrombocytotic mice. As shown, TSF gave a highly significant linear relationship between the dose of TSF and the percent 35S incorporation into platelets (9 = .99). IL-6 also showed a dose-response relationship ( quired 40,000 U/mouse (4 pg) for significant increase of percent "S incorporation into platelets of assay mice (P < .005). Figure 2 shows the results of measuring percent "S incorporation into platelets of mice after two or four injections of either HSA, 4 U of TSF, or 40,000 U of IL-6 in both normal mice and mice in rebound-thrombocytosis (RAMPS-treated mice). The results showed that in both normal mice and RAMPS-treated mice, TSF significantly (P < .005) increased percent "S incorporation into platelets of mice after two or four injections. In agreement with previous studies,I6 TSF had greater effects when administered to mice in rebound-thrombocytosis than when given to normal mice. IL-6, on the other hand, did not increase percent "S incorporation into platelets of mice after two injections, but after four injections IL-6 significantly increased platelet production (P < .OS) in both normal and rebound-thrombocytotic mice. Although not shown, platelet counts of mice treated with either IL-6 or TSF were not increased when compared with counts of mice injected with HSA.
RESULTS
Platelet size measurements on blood of the same mice as presented in Fig 2 are shown in Fig 3. TSF caused significant (P < .005 to P < .0005) increases in platelet sizes at all injection schedules in both normal mice and rebound-thrombocytotic mice when compared with other mice treated with HSA. IL-6 did not increase platelet sizes of normal mice, but there were significant (P < .OS to P < .OOOS) increases in sizes of platelets in RAMPStreated mice after IL-6 treatment. In the present study, TSF and IL-6 did not increase platelet counts of mice when measured 3 days after the initial injection. percent SAChE+ cells were counted; 4 X lo' U IL-6/mouse gave 7.1 f 1.5 (6) percent SAChE+ cells; and 10 X lo3 U IL-6/mouse, resulted in 6.9 f 0.8 (5) percent SAChE+ cells. Table 2 shows the results of measuring the percent "S incorporation into platelets of TSF assay mice after injec- Values are expressed as mean f SE (number of micehreatment). HSA was injected at 7.5 mglmouse. TSF was injected for a total dose of 4 U/mouse. IL-6 was injected for a total dose of 40,000 Ulmouse.
*Significantly lower than hematocrits of HSA-treated control mice, P < .0005. tions of a TSF preparation (Step I11 TSF)I4 that was free of 1L-6. The data show a significant linear relationship (? = .95) between the dose of TSF injected and the percent "S incorporated into platelets of assay mice, indicating that TSF, and not IL-6, is responsible for increased platelet production in these mice.
DISCUSSION
The present study shows that both IL-6 and TSF will increase percent "S incorporation into platelets of mice if given in four injections (Figs 1 and 2 ), but only TSF'is effective when the material is given in two doses (Fig 2) . Unlike TSF, IL-6 did not increase the numbers of SAChE+ cells (Fig 4) or platelet sizes (Fig 3) of normal mice. This study agrees with previous studies' showing that TSF increases both platelet production and megakaryocytopoiesis in rodents, ie, percent "S incorporation into platelets,'.'6 percent SAChE+ cells,'9 and platelet sizes.I7 Previous experiments showed that TSF will elevate platelet counts,' megakaryocyte sizes and numbers,2',22 megakaryocyte endomitosis,'*23 megakaryocyte maturation,' and megakaryo- Values are expressed as mean -C SE.
Step 111 TSF" was found to be free of IL-6 by both Western blotting techniques and by the 69 cell proliferation a s s~y . '~ *Correlation coefficient of data: r' = .95. tsignificantly greater than saline-injected control mice.
cyte DNA content? The stimulatory effects of IL-6 on megakaryocyte endomitosis and maturation have apparently not yet been tested, but in the present study IL-6 did not stimulate percent SAChE+ cell numbers and platelet sizes in normal mice. We present below additional evidence that the two cytokines are probably separate factors.
Previous studies have shown that administration of It-6 in vivo will increase platelet counts? megakaryocyte size,'5 and 75SeM incorporation into platelets4 of both mice and monkeys. Also platelet sizes were reported not to be elevated in mice by IL-6 treatment in a preliminary ~t u d y .~ However, 16 pg (160,000 U) of IL-6 were reported to increase WBC counts, without significant changes in hematocrit~~ or megakaryocyte numbers' of recipient animals. Hill et a14 showed that 8 pg of IL-6 given to mice produced an increase in megakaryocyte and granulocyte-macrophage colony-forming cells in both the BM and spleen of mice. However, Asano et als showed in primates that injection of 80 Fgkg per day of IL-6 produced a loss of body weight, anemia, and other adverse side effects. It should be mentioned that in all these studies, large doses of rIL-6 (microgram quantities) were required to increase either megakaryocytopoiesis or thrombocytopoiesis.
In in vitro studies, Ishibashi et alR and Koike et all'
showed that IL-6 increased megakaryocyte sizes. Megakaryocyte ploidy and acetylcholinesterase content of megakaryocytes in culture were also reported to be increased by IL-6 treatment," and if IL-3 was added to cultures containing IL-6, an increase in megakaryocyte colonies was observed?".' However, Bruno and Hoffman' showed that the addition of TSF or erythropoietin (Epo) to IL-6 decreased megakaryocytic colony formation. It was concluded that the effects of IL-6 are probably on accessory cells for the release or production of other cytokines? Williams et all0 showed that IL-6 would stimulate growth of immature mouse megakaryocytes. A similar conclusion was reached by other investigators",l2 who showed that IL-6 would increase the acetylcholinesterase content of cells'* without an increase in colony formation. Two recent reviews summarize this All these in vitro studies showed that IL-6 would enhance megakaryocytopoiesis, but the possibility exists that the effects may not be direct.
In the present study we used a partially purified TSF preparati~n'~ that contained a small amount of IL-6 ( -875 U of IL-6/U of TSF). Sufficient amounts of the more highly purified preparation for these studies were not available. Preliminary experiments and work presented herein showed no effects of IL-6 on percent 3sS incorporation into platelets (Fig 1) or on the percentage of SAChE+ cells when IL-6 was given in doses that were present in the TSF. Moreover, one experiment (Table 2 ) using a more highly purified preparation of TSF that was found to be free of IL-6 showed that this TSF preparation would still stimulate platelet production in rebound-thrombocytotic mice. Therefore, we do not believe that the small amount of IL-6 that was present in the TSF was responsible for the thrombocytopoietic stimulating effects seen in this study. It does not seem possible that a combination of IL-6 and other unFor personal use only. on October 24, 2017. by guest www.bloodjournal.org From known factors present in the TSF preparation could have caused the stimulation of thrombocytopoiesis observed herein, based upon our previous findings using purified TSFI4 and the data presented in Table 2 . A more likely explanation is that a specific thrombocytopoietic factor (TSF) within our preparation caused the increases in thrombocytopoiesis that we have observed. Experiments with rTSF will be necessary to resolve this issue.
The present work agrees with the work of Hill et ai4 showing that high doses of IL-6 will increase platelet production by increasing incorporation of isotopes into platelets. Moreover, the two studies agree that there is a dose-response relationship between isotope incorporation and the amounts of IL-6 injected. However, it should be noted that in both studies positive responses required multiple injections of large doses of IL-6 (in the order of 40,000 to 80,000 U/mouse, 4 to 8 Fg) for increase of isotope incorporation into platelets. In our study, two injections of IL-6 administered over a 1-day period did not elevate percent 35S incorporation into platelets of either normal or rebound-thrombocytotic mice. All other studieP showing increase of thrombocytopoiesis by IL-6 required large doses over an extended period of time. It should also be mentioned that high levels of another cytokine (rEpo) will also increase Our study agrees also with a preliminary report of Hill et al showing that mean platelet volumes were unaffected by IL-6 administration into normal mice.7 Although we showed that TSF treatment resulted in significant increases in platelet sizes of both normal and rebound-thrombocytotic mice, IL-6 did not increase platelet sizes of normal mice. However, increased platelet sizes of rebound-thrombocytotic mice were found after IL-6 injections. The reason for altered platelet sizes in rebound-thrombocytotic mice but not in normal mice after IL-6 is unknown. However, the fact that the rebound-thrombocytotic mice are more sensitive to exogenous preparations of platelet stimulating factors than are normal mice may play a role. Unlike IL-6, thrombopoietin from plasma of thrombocytopenic rabbits27 and TSF from HEK cell culture medial7 were shown previously to stimulate increases in platelet sizes of normal mice. This apparent discrepancy in activities of the two cytokines on platelet sizes illustrates another reason for suspecting that TSF and IL-6 are separate entities.
In addition to a discrepancy in the effects of TSF and IL-6 on platelet sizes, SAChE+ cells also were not altered by IL-6 treatment, whereas low doses of TSF (2 U/mouse) significantly increased (P < .005) the percent SAChE+ cells in marrow of TSF-treated mice (Fig 4) . Original studies by Jacksonz8 showed that large increases in the proportions of SAChE+ cells occurred when rats were made thrombocytopenic. This study was confirmed in thrombocytopenic mice and in additional studies using TSF from HEK cell culture media.I9 Plasma from thrombocytopenic mice that contained thr~mbopoietin,'~ but is apparently free of IL-6;' stimulated significant increases in SAChE+ cells of recipient mice. The fact that IL-6 did not incorporation into platelets of assay mice.26 increase the percentages of SAChE+ cells is another reason to suspect that IL-6 and TSF are separate cytokines.
In contrast to the results of previous s t~d i e s , "~ platelet counts were not increased by IL-6 in the present work. The reason(s) for this is probably because of different IL-6 injection schedules. All previous investigators gave large doses of IL-6 over an extended period of time (2% to 16 days), whereas in our study the effects of IL-6 were examined after administering two or four injections over a 1-to 2-day period. This schedule was chosen because our previous study* showed maximum increased platelet production in mice given TSF at this time.
Hematocrits in the present study were slightly decreased in normal mice given two injections of IL-6; no other hematocrit changes were noted. Why four injections of IL-6 did not produce anemia is unknown. Anemia was noted by Asano et a15 in monkeys given 20 to 80 Fgkg/d of IL-6. TSF did not cause significant decreases in hematocrits of treated mice, but did increase megakaryocytopoiesis and thrombocytopoiesis.
In addition to the differences in biologic responses of the two cytokines, there are several other reasons to predict that thrombopoietin and IL-6 are separate growth factors: (1) The two compounds have different molecular weights, ie, IL-6 has a molecular weight of about 26 Kd3' and the molecular weight of TSF is -15 Kd.I4 (2) Partially purified preparations of TSF (Step I11 TSF)I4 have been shown to be free of IL-6 but still increase percent 35S incorporation into platelets of immunothrombocythemic assay mice (Table 2 ). IL-6 was not found in Step I11 TSF by Western blotting techniques and by the B9 cell proliferation assay for IL-6." (3) Previously, nanogram quantities of purified TSF stimulated significant increases in percent "S incorporation into platelets of assay mice,I4 whereas in the present study and microgram quantities of pure IL-6 were required for similar stimulation of platelet production. (4) Some kidney cell lines will not produce IL-6, but produce large quantities of TSF (unpublished results). (5) IL-6 is produced by a variety of t i s~u e~,~~~~~ whereas TSF appears to be produced in vitro only by kidney cells.' (6) Recently, Hill et aI3' reported that plasma IL-6 levels were not increased by induction of thrombocytopenia in mice, indicating that IL-6 is probably not involved in stimulating platelet production in mice rendered acutely thrombocytopenic. (7) Another recent s t u d y found that IL-6 levels did not correlate with platelet counts of patients, but IL-6 was elevated in sera of patients in response to inflammation. (8) Many growth factors (including Epo) will stimulate platelet production26 in mice if given in high enough doses. (9) Unlike thrombopoietin, IL-6 has a broad range of effects in vivo,33 as well as in vitro. For these reasons, we believe that IL-6 is not thrombopoietin and that thrombopoietin, not IL-6, is the physiologic regulator of thrombocytopoiesis.
